Redcare Pharmacy's Expansion Dilemma: Growth at the Expense of Profitability

Redcare Pharmacy shares plunge over 52% YTD as strong revenue growth from Germany's E-Rezept system fails to offset a sharp cut to medium-term EBITDA margin targets.

Shares of online pharmacy operator Redcare Pharmacy are under significant pressure, hitting a one-year low of €32.24 on Tuesday. This price point marks a staggering decline of more than 52% since the start of the year. The driving force behind this sell-off is not a lack of customer growth but mounting investor concern over the company's future earnings potential.

Robust Revenue Growth Masks Underlying Issues

The company recently reported impressive top-line expansion for the full year 2025, with group revenue climbing 24.1% to €2.94 billion. A major catalyst has been the adoption of Germany's digital prescription, or E-Rezept, system. Revenue in this prescription segment nearly doubled, reaching €503 million. However, the nature of this success is proving costly. Prescription medications operate on substantially thinner profit margins compared to over-the-counter health and cosmetic products. This shifting sales mix exerted downward pressure on the adjusted gross margin, which contracted from 23.0% to 22.6% last year.

Revised Targets Trigger Market Alarm

The primary source of disappointment for the market emerged from forward-looking guidance. Management made a sharp downward revision to its medium-term profitability goal, slashing the target for the adjusted EBITDA margin from an initial figure of over 8% to a new benchmark of more than 5%. For the current fiscal year 2026, the board issued the following specific targets:

• Total revenue growth: 13 to 15 percent
• German prescription business revenue: over €670 million
• Growth in over-the-counter articles: 8 to 10 percent
• Adjusted EBITDA margin: at least 2.5 percent

This strategic pivot underscores a clear focus on capturing market share through the digital prescription channel. While successful in driving volume, this expansion is severely compressing profitability. In the absence of a clear path to improved earnings, the stock lacks a fundamental catalyst for a sustained recovery. Achieving the targeted 2.5% margin this year now stands as the essential minimum requirement for Redcare Pharmacy to begin rebuilding credibility with investors.

The current strategy presents a classic growth dilemma: rapid market share gains are being funded by a significant sacrifice in near-term earnings power. Until the company can demonstrate an ability to balance this equation, shareholder confidence is likely to remain fragile.